TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03710096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: macGrath
Description: in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh's
Description: in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
Study: NCT04010734

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography
Description: The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography
Description: The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH).
Study: NCT04204343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.7 ml/kg
Description: Bupivacaine 0.25% 0.7 ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5 ml/kg
Description: Bupivacaine 0.25% 0.5 ml/kg
Study: NCT04185064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game Ready ATX shoulder wrap; Game Ready GRPro 2.1
Description: the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.

Intervention type: DEVICE
Group type: OTHER
Intervention: Game Ready ATX shoulder wrap; Game Ready GRPro 2.1
Description: the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
Study: NCT01193699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-P-INF alpha-2b (P1101)
Description: µg (starting with 50 µg), subcutaneously, 2-weekly administration
Study: NCT03583697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
Study: NCT04184713

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
Study: NCT00608660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: staging acupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture and moxibustion
Description: staging acupuncture and moxibustion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: staging electroacupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture along yangming tendons
Description: staging acupuncture along Yangming musculature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: non-staging acupuncture
Study: NCT04721171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Bridge device
Description: he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: The Bridge device
Description: he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
Study: NCT01457144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiBVD
Description: Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2
Study: NCT01228474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Select the Number of embryos to transfer
Description: Select the Number of embryos to transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Select the Number of embryos to transfer
Description: Select the Number of embryos to transfer
Study: NCT01753141

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.
Description: Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
Study: NCT04466865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case communication tool training
Description: The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of kidney disease. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning the intervention is designed to lead to a discussion of participants preferences and consideration of outcomes.~The nephrologist verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The nephrologist also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences.
Study: NCT02084212

Intervention type: OTHER
Group type: OTHER
Intervention: Microperimetry
Study: NCT02423109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: contact lens
Study: NCT02214199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative Therapy Techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercises
Study: NCT02423109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A
Description: contact lens
Study: NCT03161678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
Study: NCT03136549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermo-softening
Description: The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room temperature
Description: nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
Study: NCT03767062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax
Description: An antiepileptic agent used for migraine prophylaxis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater Occipital Nerve Block + Supratrochlear Nerve Block
Description: An injection to paralyze the occipital and supratrochlear nerves.
Study: NCT02423109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enfilcon A
Description: contact lens
Study: NCT04561336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab in combination with cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: avelumab in combination with cetuximab
Study: NCT01706263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Cleanser
Description: Available over the counter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Treatment
Description: Available over the counter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
Description: Available over the counter.
Study: NCT01477424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Description: The maximum dose of PA21 will be 15.0 g/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Description: The maximum dose of PA21 will be 15.0 g/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: The maximum dosage of Warfarin will be 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: The maximum dosage of Warfarin will be 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: The maximum dosage of Warfarin will be 10 mg/day
Study: NCT04643392

Intervention type: PROCEDURE
Intervention: Complex decongestive physiotherapy
Description: Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
Study: NCT00931996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic
Description: Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
Study: NCT01413763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod cream 3.75%
Description: 3.75% cream, applied daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: placebo cream applied daily for 2 weeks
Study: NCT02330744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-positive AAT
Description: One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control AAT
Description: One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
Study: NCT01897714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04864301

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Stretching Measurement Technique
Description: The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Stretching Measurement Technique
Description: The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus.
Study: NCT03102333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variable-rate Feedback Infusion mode
Description: The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Constant-rate Infusion mode
Description: The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
Study: NCT03124446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based College
Description: MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
Study: NCT03332290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sport practice
Description: the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sport practice
Description: the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
Study: NCT04680091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: single oral dose, 400 mg, fed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrotinib Maleate
Description: single oral dose, 400 mg, fed.
Study: NCT02979990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructional Video
Description: The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Video
Description: The control group will have access to a video about the IVF process
Study: NCT02686775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient coach
Study: NCT04680091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: single oral dose, 600 mg, fasted, at bedtime.
Study: NCT02236442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation to use global headache treatment protocol
Description: The global treatment protocol is :~1. Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~2. Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~3. Provide a sound-proof helmet to the patient.~4. Provide a light-blocking google to the patient.~5. If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~6. If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient.
Study: NCT04236479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MSC
Description: Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
Study: NCT03740841

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interactive story teller LUNII
Description: Use of the interactive story teller LUNII by the child from the pre-operative visit to the discharge.
Study: NCT02734602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
Study: NCT02686775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study: NCT01528800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K1
Description: 10mg orally three times a week for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Methylcellulose
Description: 10mg orally three times a week for 12 months